Advertisement
Effective at the close of the TAP transaction, Takeda PharmaceuticalsNorth America, Inc. and Takeda Global Research & Development Center, Inc. willreport to Takeda America Holdings, Inc. Alan MacKenzie, the current presidentof TAP and a former president of Takeda Pharmaceuticals North America, Inc.has been named executive vice president of Takeda America Holdings.
Advertisement
MacKenzie will also serve as CEO of Takeda Pharmaceuticals North America,Inc. in addition to his role as executive vice president of Takeda AmericaHoldings.
Mark Booth, current president of Takeda Pharmaceuticals North America,Inc., will continue to lead the company until the TAP transaction is closedand has agreed to continue on with the company for some period thereafter tosupport integration activities.
Reporting to MacKenzie as president of Takeda Global Research &Development Center, Inc. will be Nancy Joseph-Ridge, M.D., currently TAP'svice president of research and development. Dr. Joseph-Ridge will also assumeher position effective the close of the TAP transaction.
"I have great confidence in Takeda's proposed new leadership for theUnited States, an important market for Takeda's global growth plans," saidYasuchika Hasegawa, president, Takeda Pharmaceutical Company Limited. "AlanMacKenzie not only helped launch both TPNA and its first product, Actos, hehas been instrumental in helping create success at Takeda companies for morethan 22 years. Dr. Nancy Joseph-Ridge is a well-known and highly respectedphysician, researcher and strong leader with an unwavering commitment toscientific excellence. I would also like to take this opportunity to thankMark Booth for his many contributions to Takeda and wish him well in hisfuture endeavors."
MacKenzie first joined TAP as a sales representative in 1985 and served invarious senior-level roles for TAP, including vice president of sales anddirector of marketing. He holds a B.S.N. from Wagner College, a B.A. ineconomics from City University of New York, and a M.B.A. from the Universityof Chicago.
Prior to joining TAP in 2002, Dr. Joseph-Ridge worked for Searle, whichlater became part of Pfizer, in drug safety and clinical development. Shepreviously held clinical and academic roles in Chicago at Rush-Presbyterian-St.Luke's Medical Center and the University of Chicago Hospitals. She receivedher M.D. from the University of Illinois at Chicago.
Takeda Pharmaceuticals North America, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is awholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largestpharmaceutical company in Japan. In the United States, Takeda currentlymarkets products for diabetes, insomnia, wakefulness and gastroenterology.Through the Takeda Global Research & Development Center, Inc. the company hasa robust pipeline with compounds in development for diabetes, cardiovasculardisease and other conditions. Takeda is committed to striving toward betterhealth for individuals and progress in medicine by developing superiorpharmaceutical products. To learn more about the company and its products,visit http://www.tpna.com.
SOURCE Takeda Pharmaceuticals North America, Inc.
